Welcome to Oncology & Cancer Conferences

Upcoming Oncology & Cancer Conferences

Oncology & Cancer Conferences 2017

Oncology & Cancer Conferences 2018

Conferenceseries Destinations


The conferences on cancer & oncology provide a platform for researchers and decision makers in cancer research to present their latest findings and learn about all the important developments in cancer research. Target audience for the conference include Principle Investigators & Directors, Cancer Specialists, Medical Oncologists, Pathologists, Radiologists, Cancer Nurse Practitioners, Laboratory Researchers, Group Leaders, Cancer Diagnostic Professionals, Cancer & Oncology Societies Professionals, Bio-Medical Company professionals, Corporate Cancer Research Professionals, Young Researchers, Students, Delegates from Clinical Research Centres etc.

CME Conferences provides a platform to the professionals/physicians to meet requirements for maintenance of licensure, maintenance of specialty board certification, credentialing, membership in professional societies, and other professional honours. Through our conferences, CME also provides an opportunity to share medical knowledge, help physicians understand their association to the health care delivery system and accentuate the need for system-based practices. Attending live CME conferences provide numerous benefits, and while they cannot replace the convenience of online CME, conferences are excellent resources for education and camaraderie. Those in the medical field maintain competence and learn about new and developing areas of their field through these CME conferences. CME is crucial to the prosperity of health care providers, it allows a practitioner to learn and discover viable ways to improve on the patient care they deliver and effectively manage a career in the ever-changing landscape of the medical industry. The requirements or acceptable level of CME vary across medical disciplines, but they are equally important no matter the specialty or scope of practice in which a provider is engaged.

Continuing medical education allows health care providers to:

  • Refine skills to improve overall patient care
  • Stay current with the latest developments within their specialty
  • Address real-world challenges that health care professionals face day to day
  • Gain professional growth and a means to advance career status
  • Meet licensing/certification requirements
  • Learn effective medical team management skills
  • Earn membership in professional organizations

The ultimate outcome of well-planned Continuing Professional Development (CPD) is that it safeguards the public, the employer, the professional and the professional’s career. A CPD conference ensures your capabilities keep pace with the current standards of others in the same field. CPD ensures that you maintain and enhance the knowledge and skills you need to deliver a professional service to your customers, clients and the community. . CPD conferences is important as it helps to ensure that further learning is progressed in a structured, practical and relevant way to guarantee that there are applied efficiencies in learning. Well-crafted and well-delivered CPD conferences provide delivers successive benefits at every level within the education system. .CPD is intended to support future professional development and in turn giving the potential to expand your scope of practice.

Global cancer diagnostics market was estimated to be USD 101.0 billion in 2013; it is estimated to grow at a CAGR of 7.6% from 2014 to 2020. Similarly cancer biomarkers market is expected to reach USD 15,973.8 Million by 2020. In 2010, over all cancer market was valued at $54 billion, forecasted a Compound Annual Growth Rate (CAGR) growth to be $81 billion by 2016. There are seven major cancer markets (USA, France, Germany, Italy, Spain, United Kingdom and Japan) represented almost 79% of the 2010 global cancer market ($43 billion).

Cancer has a very high impact on United States. In 2017, approximately 2,245,110 new cases of cancer will be diagnosed in the United States and 595,690 people will die from the disease. The number of people living with cancer reached nearly 14.5 million in 2014 and is predicted to reach 19 million by 2024. Final expenditures for cancer care in the United States totalled almost $125 billion in 2010 and anticipated to reach up to $156 billion in 2020.

A new study demonstrates that the USA spends significantly more than Europe on malignancy mind however Europe has a higher mortality rate. The highest malignancy rate was found in France with 385 men for each 100,000 being analysed in 2012. The highest cancer rate was found in Denmark with 329 women per 100,000 being diagnosed in 2012. In UK male cancer rate stands at 33rd position and female cancer rate stands at 12th position in the world with 280 cases per 100,000 people.

In Middle-East, cancer diagnostics and therapeutics market as of now is estimated to be $467.04 million in 2015 and is anticipated to achieve USD 4 Billion by 2020 with a development rate of 13%. For instance, almost 50% of breast cancer patients in the Middle East are diagnosed at a median age of 49-52, compared to a median age of 63 in Western countries.According to the World Health Organization, Asia's prevalence of cancer deaths may climb from 45% to 163 % which approximately 100,000 people by 2030. Rate of cancer cases in Asia may jump by almost 60% to 7.1 million new cases a year by 2020. The incidence of cancer cases is estimated to increase from 6.1 million in 2008 to 10.6 million in 2030, due to ageing and growing populations, lifestyle and socioeconomic changes.

There are recent advancements in the cancer treatments & cancer care is accelerating. A cluster of innovative treatments, often combined with other new or existing medicines, and frequently associated with biomarkers, are emerging from the research and development pipeline. Over the past five years, 70 new oncology treatments have been launched and are being used to treat over 20 different tumour types. North America dominates the market for cancer drugs as the region houses companies engaged in the development of cancer drugs. Japan has largest share to the total Asia Pacific cancer drug market due to the high prevalence of cancer in Japanese population. The total healthcare expenditure of japan was $495 billion in 2013. However, the Asian market is slated to grow at the highest CAGR in the coming five years and serves as a revenue pocket for the companies operating in the cancer diagnostics market. Oncology spending remains concentrated to America and Europe which totally accounts for 65% of the total market. Targeted therapies have increased their share of global oncology from 11 percent to 46 percent last year. Some of the major players in the global cancer diagnostics system market include Agilent Technologies, Thermo Fisher Scientific,  Illumina, Becton, Dickinson and Company ,  GE Healthcare , QIAGEN , Abbott Laboratories, Roche Diagnosticsm, Siemens Healthcare, Philips Healthcare and C.R. Bard among others.